Drug
Dnl628
Dnl628: highest development phase Phase 1, developed by Denali Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Denali Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| DNL628 NCT07328451 | Phase 1 | Alzheimer Disease, Early Onset |
Latest
No recent events.
Follow Dnl628 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.